FY2021 · ended Dec 31, 2021 · Revenue $0 · Filed Mar 15, 2023
Quoin Pharmaceuticals Ltd. (QNRX) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$0
Net income
$-15.80M
-76.3% vs prior year
Operating cash flow (TTM)
$-15.27M
-42.8% vs year-ago TTM
Free cash flow
$-4.92M
+16.9% vs prior year
EPS
$-0.01
Dividend per share
None
Shares outstanding
52.44M
+486.1% vs prior year
Net cash
$5.04M
FY 2020
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- QNRX (Nasdaq)
- Incorporated in
- Israel
- Headquarters
- Ashburn, VA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1671502
- Former names
- Quoin Pharmaceuticals, Ltd. (until Sep 1, 2026); Cellect Biotechnology Ltd. (until Oct 15, 2021); Cellect Biomed Ltd. (until Jul 7, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 |
| Net income | -$15.8M | -$9.0M | -$8.7M | -$9.4M | -$21.5M |
| Diluted EPS | — | — | — | — | -$0.01 |
| Operating cash flow | -$13.5M | -$7.9M | -$7.9M | -$8.5M | -$5.7M |
| Total assets | $20.4M | $15.7M | $12.2M | $14.5M | $9.4M |
| Total liabilities | $7.3M | $6.5M | $6.5M | $7.1M | $8.7M |
| Stockholders' equity | $13.1M | $9.2M | $5.7M | $7.4M | $657,032 |
| Cash and investments | $18.7M | $3.6M | $2.4M | $2.9M | $7.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 20, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 22, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 10, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
Aug 28, 2026 | Aug 27, 2026 |
All 581 Quoin Pharmaceuticals Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.